Pulsatile gonadotropin-releasing hormone therapy in persistent amenorrheic weight- recovered anorexia nervosa patients Natacha Germain, M.D., Ph.D., Anaïs.

Slides:

Advertisements

Similar presentations

Can Pregnancy Stop Cyclical Attacks of Porphyria?

Advertisements

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Who requests their sperm donor's identity

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Leptin levels and luteinizing hormone pulsatility in normal cycling women and their relationship to daily changes in metabolic rate Rebecca M. Fenichel,

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Bjørn Bay, M. D. , Erik Lykke Mortensen, M. Sc

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Michael M. Alper, M.D. Fertility and Sterility

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Impact of fatness, insulin, and gynecological age on luteinizing hormone secretory dynamics in adolescent females Josephine Z. Kasa-Vubu, M.D., Vandana.

Lauren Groskaufmanis, M.P.H., Saba W. Masho, M.D.

The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.

How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization Robert L. Klitzman, M.D. Fertility.

A comparison of blood spot vs

Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency Carrie.

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Oocyte cryopreservation

Leptin levels and luteinizing hormone pulsatility in normal cycling women and their relationship to daily changes in metabolic rate Rebecca M. Fenichel,

Prevalence of premature urinary luteinizing hormone surges in women with regular menstrual cycles and its effect on implantation of frozen-thawed embryos

Efficacy of tibolone as “add-back therapy” in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids Edward.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Robert F. Casper, M.D. Fertility and Sterility

Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain Mohamed A. Bedaiwy,

Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: a phase II, randomized, dose-finding study Donald Tredway, M.D., Ph.D.,

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

Introduction Fertility and Sterility

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Evaluation of diagnostic testis biopsy and the repetition of testicular sperm extraction surgeries in infertility patients Alayman Hussein, M.B.B.C.H.,

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

David E. Reichman, M. D. , Stacey A. Missmer, Sc. D. , Katharine F

Fertility and Sterility

Effectiveness of highly purified human menopausal gonadotropin vs

Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D

Website quality assessment: Mistaking apples for oranges

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Antecubital vein venous sampling does not distort circulating levels of peptide and sex steroid hormones Michael P. Diamond, M.D., Michael Kruger, M.S.,

Efficacy of luteinizing hormone activity in patients undergoing in vitro fertilization and treated only with low-dose recombinant choriogonadotropin alfa.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.

Fertility and Sterility: an evaluation

Paolo Moghetti, M.D. Fertility and Sterility

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

Fertility and Sterility

Ronald M. Yang, M. D. , Richard A. Fefferman, M. D. , Charles E

Prolactin inhibits oocyte release after gonadotropin stimulation in the rat: Putative mechanism involving ovarian production of beta-endorphin and prostaglandin

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Clinical and laboratory characteristics of adolescents with both polycystic ovary disease and anorexia nervosa Orit Pinhas-Hamiel, M.D., Nurit Pilpel,

The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.

In vitro sildenafil citrate use as a sperm motility stimulant

Soluble HLA-G in the peritoneal fluid of women with endometriosis

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment Daniel Bodri, M.D., M.Sc.,

Presentation transcript:

Pulsatile gonadotropin-releasing hormone therapy in persistent amenorrheic weight- recovered anorexia nervosa patients Natacha Germain, M.D., Ph.D., Anaïs Fauconnier, M.D., Jean-Philippe Klein, M.D., Ph.D., Amélie Wargny, M.Sc., Yadh Khalfallah, M.D., Ph.D., Chrysoula Papastathi-Boureau, M.D., Bruno Estour, M.D., Ph.D., Bogdan Galusca, M.D., Ph.D. Fertility and Sterility Volume 107, Issue 2, Pages 502-509 (February 2017) DOI: 10.1016/j.fertnstert.2016.10.032 Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Basal gonadotropic assessment in the three groups of the study. Basal GnRH test results for (A) LH and (B) FSH. Luteinizing hormone and FSH plasma level response after IV injection of 100 μg of GnRH. (C) Luteinizing hormone plasma level pulse assessed by every 20 minutes samplings for 3 hours. Fertility and Sterility 2017 107, 502-509DOI: (10.1016/j.fertnstert.2016.10.032) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Hormonal monitoring of inductions. (A) Estradiol, (B) LH, and (C) P changes during induction in the three groups of the study. All data were included in figures and statistics analysis whether or not there were ovulation and fecundation. Fertility and Sterility 2017 107, 502-509DOI: (10.1016/j.fertnstert.2016.10.032) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions